Antibiotics Market Size & Share, by Drug Class (Beta Lactam & Beta Lactamase Inhibitors, Macrolide); Drug Origin (Natural, Semisynthetic, Synthetic); Spectrum of Activity (Broad-Spectrum, Narrow-Spectrum); Indication (Skin Infections, Respiratory, Gastrointestinal, UTIs, Blood Stream, Clostridium Difficile, Ear Infections); End-user (Hospitals, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4465
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Antibiotics Landscape

top-features-companies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company
    • Teva Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Lupin Limited
    • Melinta Therapeutics, LLC
    • Bayer AG  

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • GlaxoSmithKline plc and Spero Therapeutics have announced an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic that is anticipated to be used to treat complex urinary tract infections. Its 3rd phase clinical trial is estimated to start in 2023.

  • Teva Pharmaceuticals Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets as a therapeutic equivalent to Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. A variety of bacterial infections and rheumatic fever attacks are projected to be treated with these tablets in patients allergic to penicillin.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4465
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of respiratory diseases, surge in drug combinations over mono-therapy, escalation in urinary tract infections (UTIs) are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Side effects associated with antibiotics, stringent regulatory procedures, and escalation in antibiotic resistance are estimated to hamper the market growth.

The market in Asia Pacific is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, drug origin, spectrum of activity, indication, end-user, and by region.

The gastrointestinal segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying